[Form 4] Vicarious Surgical Inc. Insider Trading Activity

Rhea-AI Filing Summary

Vicarious Surgical director Ahmad Fuad acquired a stock option on June 27, 2025 giving the right to purchase 8,003 Class A common shares at an exercise price of $7.61. The option is reported as directly beneficially owned and has an expiration date of June 26, 2035.

The filing states the shares underlying the option will vest on June 27, 2026 (or one day prior to the issuer's next annual meeting), subject to continued service. The Form 4 was executed by an attorney-in-fact on August 11, 2025. The disclosure shows a routine director option grant with defined exercise price, vesting schedule, and expiration; no sales or dispositions are reported here.

Positive

• Director Ahmad Fuad acquired 8,003 stock options reported on 06/27/2025 with clear terms disclosed
• Vesting is specified (vesting on 06/27/2026 or one day prior to the next annual meeting), providing transparency on service conditions
• Exercise price and expiration are disclosed (exercise price $7.61, expiration 06/26/2035), clarifying potential future dilution timing

Negative

• None.

Insights

Securities Analyst

TL;DR: Director received a standard option grant for 8,003 shares at $7.61, vesting in one year — routine disclosure with limited standalone market impact.

The Form 4 documents an acquisition of a stock option by Director Ahmad Fuad on 06/27/2025 for 8,003 underlying Class A shares at a $7.61 exercise price, expiring 06/26/2035. The filing clarifies the vesting date (06/27/2026 or one day before the next annual meeting) and that ownership is direct. From a securities perspective, this is a routine officer/director compensation disclosure required under Section 16 and, by itself, does not signal a material change in company valuation or capital structure.

Corporate Governance Expert

TL;DR: Disclosure shows a time‑based retention/compensation award to a director; documented vesting and expiration dates provide transparency but are not material alone.

The filing provides clear terms: grant date 06/27/2025, vesting by 06/27/2026 subject to continued service, exercise price $7.61, and expiration 06/26/2035. Such option grants to directors are common as alignment and retention mechanisms. The Form 4 meets Section 16 reporting requirements and offers investors transparent documentation of director compensation timing and potential dilution, though it does not disclose any immediate exercise or sale activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ahmad Fuad

(Last) (First) (Middle)

C/O VICARIOUS SURGICAL INC.

78 FOURTH AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Vicarious Surgical Inc. [ RBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.61	06/27/2025		A		8,003		(1)	06/26/2035	Class A Common Stock	8,003	$0.00	8,003	D

Explanation of Responses:

1. All of the shares underlying this option will vest on June 27, 2026, or one day prior to the Issuer's next Annual Meeting of Shareholders, whichever is earlier, subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Erin Checka, Attorney-in-Fact	08/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Ahmad Fuad report on the Form 4 for RBOT?

The Form 4 reports the acquisition of a stock option on 06/27/2025 giving the right to purchase 8,003 Class A common shares.

What is the exercise price and expiration of the option reported by RBOT director?

The option has an exercise price of $7.61 and an expiration date of 06/26/2035.

When do the options vest according to the filing?

All shares underlying the option vest on 06/27/2026 or one day before the issuer's next annual meeting, subject to continued service.

What is the reported ownership form for the acquired derivative securities?

The Form 4 reports the ownership form as Direct (D) for the acquired options.

Who signed the Form 4 and when was it executed?

The filing was executed by Erin Checka, Attorney-in-Fact on 08/11/2025.